Stericycle Inc. (SRCL) Price Target Cut to $85.00 by Analysts at Robert W. Baird
Stericycle Inc. (NASDAQ:SRCL) had its price objective cut by analysts at Robert W. Baird from $99.00 to $85.00 in a note issued to investors on Friday. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 7.24% from the stock’s current price.
SRCL has been the subject of a number of other reports. Macquarie started coverage on Stericycle in a research report on Thursday, August 25th. They issued a “neutral” rating and a $96.00 price target for the company. Jefferies Group reaffirmed a “buy” rating and set a $112.50 target price (down from $125.00) on shares of Stericycle in a research report on Wednesday, September 7th. Zacks Investment Research raised Stericycle from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Imperial Capital lowered Stericycle from an “in-line” rating to an “underperform” rating and decreased their target price for the company from $100.00 to $93.50 in a research report on Friday, July 29th. Finally, Wellington Shields lowered Stericycle from an “accumulate” rating to a “hold” rating in a research report on Friday, July 29th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $104.95.
Shares of Stericycle (NASDAQ:SRCL) traded up 0.08% during midday trading on Friday, hitting $79.32. 137,017 shares of the stock were exchanged. The stock’s 50-day moving average price is $84.23 and its 200-day moving average price is $102.26. The firm has a market capitalization of $6.75 billion, a price-to-earnings ratio of 27.92 and a beta of 0.27. Stericycle has a 1-year low of $76.76 and a 1-year high of $151.57.
Stericycle (NASDAQ:SRCL) last released its quarterly earnings results on Thursday, July 28th. The company reported $1.18 EPS for the quarter, meeting analysts’ consensus estimates of $1.18. The business earned $891.60 million during the quarter, compared to analyst estimates of $910.29 million. Stericycle had a return on equity of 14.84% and a net margin of 7.22%. Stericycle’s quarterly revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.14 EPS. On average, analysts forecast that Stericycle will post $4.67 EPS for the current year.
In other Stericycle news, EVP John P. Schetz sold 1,398 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $81.85, for a total value of $114,426.30. Following the completion of the transaction, the executive vice president now owns 1,088 shares in the company, valued at approximately $89,052.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rodney F. Dammeyer sold 10,188 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $85.50, for a total value of $871,074.00. Following the completion of the transaction, the director now owns 10,188 shares of the company’s stock, valued at approximately $871,074. The disclosure for this sale can be found here. 3.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of SRCL. Vanguard Group Inc. increased its stake in shares of Stericycle by 1.8% in the second quarter. Vanguard Group Inc. now owns 7,471,494 shares of the company’s stock worth $777,932,000 after buying an additional 135,168 shares during the period. State Street Corp increased its stake in shares of Stericycle by 0.5% in the first quarter. State Street Corp now owns 3,593,337 shares of the company’s stock worth $453,442,000 after buying an additional 19,317 shares during the period. Baillie Gifford & Co. increased its stake in shares of Stericycle by 77.2% in the second quarter. Baillie Gifford & Co. now owns 2,940,515 shares of the company’s stock worth $306,166,000 after buying an additional 1,281,519 shares during the period. Jana Partners LLC acquired a new stake in shares of Stericycle during the first quarter worth about $305,997,000. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of Stericycle by 0.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,289,722 shares of the company’s stock worth $288,940,000 after buying an additional 19,063 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.
Stericycle Company Profile
Stericycle, Inc is a business-to-business services provider with a focus on regulated and compliance solutions for healthcare, retail and commercial businesses. The Company’s solutions include the collection and processing of specialized waste for disposal, the collection of personal and confidential information for secure destruction, and a range of training, consulting, recall/return, communication and compliance services.
Receive News & Ratings for Stericycle Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stericycle Inc. and related companies with MarketBeat.com's FREE daily email newsletter.